Perspectives on preventative health, executive longevity, and the art of medicine in active practice — prioritizing contextual interpretation and longitudinal oversight above automated algorithms.
A pre-symptomatic framework for neuroprotection integrating familial pedigree, APOE genetics, metabolic biomarkers, structured cognitive baselines, and volumetric brain imaging.
Read Clinical Perspective
Why conventional 10-year risk calculators fail adults under 55 and how advanced atherogenic biomarkers (ApoB, Lp(a)), retinal scans, and plaque imaging unmask silent disease.
Read Clinical Perspective
The delicate balance between life-saving early detection and the psychological and physical harms of over-investigation, evaluating liquid biopsies, tumor markers, and MRI.
Read Clinical PerspectiveNeurodegenerative illnesses — including Alzheimer’s disease, vascular dementia, and frontotemporal lobar degeneration — do not begin abruptly in later life. Pathological cascades commence twenty to thirty years before memory or executive complaints emerge in clinic. The primary clinical opportunity exists in the pre-symptomatic phase.
Assessment commences with generational analysis: identifying the precise age of onset in first-degree relatives, patterns of cardiovascular comorbidities, and family histories of early vascular impairment.
Cerebral health is inextricably linked to microvascular health. Optimizing blood pressure variability, systemic inflammatory markers, and glycemic control directly preserves cerebral perfusion. Furthermore, we monitor sleep architecture and nocturnal oxygenation via multi-week medical diagnostic devices to evaluate glymphatic clearance — the brain’s waste-removal mechanism during deep slow-wave sleep.
Rudimentary bedside tests routinely fail high-functioning executives whose cognitive reserve masks early functional changes. We establish baseline metrics across processing speed, attention, visuospatial reasoning, and executive memory, tracking longitudinal deviation against personal baselines over years.
APOE-ε4 allele status is framed strictly probabilistically: carrying one or two risk alleles is not deterministic. A high-risk genotype allows us to implement aggressive lifestyle, metabolic, and vascular counter-measures decades ahead of symptomatic risk.
Alongside reversible metabolic factors (active B12, folate, homocysteine, ApoB), we monitor emerging plasma proteomics such as phosphorylated tau (pTau187) and neurofilament light chain (NfL), combined with high-field brain MRI with AI hippocampal volumetrics to identify microvascular small vessel disease early.
Atherosclerosis is a multi-decade biological process. For a tragic number of people, the very first indication of cardiovascular disease is an acute myocardial infarction or stroke. Yet the overwhelming majority of heart attacks are entirely preventable when atherogenic drivers and vascular pathology are identified and stabilized early.
Tools like QRISK rely on 10-year short-term population probabilities. Because age dominates these algorithms, an asymptomatic 42-year-old with significant soft atheromatous plaque will almost invariably score “low risk,” creating false reassurance during the exact window when intervention is most curative.
Standard lipid panels provide incomplete data. Total cholesterol and calculated LDL overlook particle quantity. We evaluate Apolipoprotein B (ApoB) — the total number of atherogenic circulating particles — and genetically determined Lipoprotein(a) [Lp(a)], coupled with systemic high-sensitivity C-reactive protein (hs-CRP).
We deploy non-invasive AI-enhanced retinal imaging as a direct proxy for coronary microvascular health without radiation. Where clinically indicated, Coronary Artery Calcium (CAC) scoring and CT Coronary Angiography (CTCA) visualize non-calcified soft plaque burden directly, transforming abstract risk calculations into definitive anatomical targets.
Detecting early plaque in a 40-year-old represents an urgent opportunity for plaque stabilization and reversal through targeted lifestyle adaptation and modern therapeutics (such as statins, PCSK9 inhibitors, or bempedoic acid). Through serial surveillance, we confirm that chosen interventions are actively halting disease progression.
The desire for exhaustive cancer screening is entirely understandable. However, in medicine, more testing is not synonymous with better care. Indiscriminate screening introduces genuine risks of physical harm, psychological anguish, and invasive procedures for clinically insignificant anomalies that would never have threatened life.
Conventional tumour markers (such as CEA, CA125, or CA19-9) were developed for monitoring response to established cancer therapy, not for primary screening in healthy individuals. When applied indiscriminately, they yield high rates of both false alarms and false reassurance.
Multi-cancer early detection tests analyzing cell-free circulating DNA represent a genuine frontier. However, critical caveats exist: sensitivity for Stage I tumours remains moderate, negative results do not exclude malignancy, and some positive signals detect indolent micro-neoplasms that would have resolved naturally via immune surveillance.
Whole-body MRI is heavily marketed by retail clinics. Yet in healthy individuals, it identifies benign incidental findings (incidentalomas) in up to 30% of scans — harmless renal cysts, benign hepatic haemangiomas, and thyroid nodules that trigger cascading cycles of follow-up scans, biopsies, and anxiety.
We anchor cancer surveillance in proven mortality-reducing interventions: scheduled colonoscopy, cervical cytology, mammography, and low-dose CT for individuals with substantial smoking history — supplemented selectively with genetic risk profiling (BRCA, Lynch syndrome). Every screening decision is made transparently, matching medical evidence with individual patient values.
